GLP-1 Medications Linked to Reduced Breast Cancer Risk in Women, New Study Finds
Emerging research presented at the American Society of Clinical Oncology (ASCO) 2026 meeting suggests that GLP-1 receptor agonists—commonly used for weight control, for managing blood sugar (glucose) levels in people with Type 2 diabetes, cardiovascular diseases, addiction and kidney and liver diseases—may significantly lower breast cancer risk in women.
An observational analysis of over 110,000 cases found that women using GLP-1 medications were 35% less likely to be diagnosed with breast cancer, highlighting a potential new benefit beyond metabolic health.
New findings presented at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) point to a promising potential benefit of GLP-1 receptor agonists: a reduced risk of breast cancer in women.
The observational study, led by Elizabeth McDonald, MD, PhD, a professor of radiology at the University of Pennsylvania Perelman School of Medicine, analyzed data from more than 110,000 cases. Researchers found that women taking GLP-1 medications were approximately 35% less likely to develop breast cancer compared to those not using these therapies.
GLP-1 drugs have already demonstrated benefits across various health conditions, including weight control, management of blood sugar (glucose) levels in people with Type 2 diabetes, cardiovascular diseases, addiction and kidney and liver diseases. However, their impact on cancer risk has remained relatively underexplored—making these findings especially noteworthy.
The study, managed by the American College of Radiology (ACR), underscores a potential link between GLP-1 use and lower breast cancer incidence. While the results are encouraging, experts caution that the research is observational and does not establish a direct cause-and-effect relationship.
Etta D. Pisano, MD, FACR, Chief Research Officer at the ACR and a senior author of the study, emphasized the importance of further investigation. She noted that advancements in screening and treatment have already reduced breast cancer mortality by more than 40% over the past four decades, and preventive strategies could offer an even greater impact.
According to Pisano, the next step is conducting large-scale prospective studies to determine whether GLP-1 medications can play a role in breast cancer prevention. Such research could potentially reshape clinical approaches and public health strategies if a causal link is confirmed.
In response to these findings, ACR leaders are advocating for increased funding and expanded research efforts to better understand how GLP-1 therapies may influence cancer development.
As interest in GLP-1 medications continues to grow, this new data adds to a rapidly evolving body of evidence suggesting these drugs may offer benefits far beyond weight management—potentially opening new avenues in oncology prevention.
Sources:
https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
Hannah Murphy | June 01, 2026 | Radiology Business | Womens Imaging